Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions - FiercePharma
| TLX Stock | 24.55 0.19 0.77% |
Slightly above 62% of Telix Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Telix Pharmaceuticals suggests that many traders are alarmed. Telix Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Telix Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Telix |
Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions FiercePharma
Read at news.google.com
 |
Telix Pharmaceuticals Fundamental Analysis
We analyze Telix Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Telix Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Telix Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Telix Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Telix Pharmaceuticals Related Equities
| 29M | 29Metals | 2.78 | ||||
| MFF | MFF Capital | 0.93 | ||||
| CIW | Clime Investment | 0.00 | ||||
| AUI | Australian United | 0.09 | ||||
| RG8 | REGAL ASIAN | 0.48 | ||||
| ARG | Argo Investments | 0.76 |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.